[Inhibitory effect of lidamycin upon vasculogenic mimicry and its induction of apoptosis in glioma cells].
OBJECTIVE
To evaluate the in vitro effects of lidamycin upon vasculogenic mimicry and apoptosis induction in glioma cells.


METHODS
Tube formation assay was performed to estimate the inhibitory effects of lidamycin upon vasculogenic mimicry in C6 and U87 glioma cells. The vasculogenic mimicry of glioma cells was photographed and enumerated. Annexin V-FITC/PI was used for determination of glioma cell apoptosis with flow cytometry.


RESULTS
Vasculogenic mimicry assay indicated that 0.1 nmol/L, 0.5 nmol/L and 1 nmol/L lidamycin showed significant inhibition of vasculogenic mimicry in C6 and U87 cells. Comparing with C6 control group (14.7 +/- 1.2), 0.1 nmol/L (12.7 +/- 0.6), 0.5 nmol/L (9.0 +/- 1.7) and 1 nmol/L (4.7 +/-0.6) lidamycin inhibited vasculogenic mimicry in C6 cells with statistical significances (P = 0.013, P = 0.005 and P = 0.0002 respectively). Comparing with U87 control group (14.7 +/- 1.2), the vasculogenic mimicry of 0.1 nmol/L (10.0 +/- 2.0), 0.5 nmol/L (8.3 +/- 1.5) and 1 nmol/L lidamycin (4.3 +/- 0.6) treated U87 cells showed statistical significances (P = 0.025, P = 0.00 and P = 0.0009 respectively). The apoptotic ratios of same dosa ges lidamycin treated C6 cells and U87cells showed a similar tendency as vasculogenic mimicry inhibition (P < 0.001). Lidamycin was more potent than neocarzinostatin in vasculogenic mimicry inhibition and apoptosis induction of C6 cells and U87 cells. Conclusion Lidamycin can inhibit vasculogenic mimicry and promote apoptosis of glioma cells. Thus it is a promising drug in glioma treatment. Further researches on the therapeutic efficacy of enediyne antibiotics in glioma are needed.
Li
Xing-Qi
XQ
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Zhang
Sheng-Hua
SH
Ouyang
Zhi-Gang
ZG
Zhen
Yong-Su
YS
D000617:Aminoglycosides / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D053281:Enediynes / Q000494:pharmacology*; D005910:Glioma / Q000473:pathology*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000473:pathology*; D051381:Rats
D000617:Aminoglycosides; D000903:Antibiotics, Antineoplastic; D053281:Enediynes; C058024:C 1027